Compare Cytokinetics Inc (CYTK) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs SYSCO Corporation — how do they compare? Cytokinetics Inc trades at $76.22 (market cap $10.63B), while SYSCO Corporation trades at $85.09 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 3.8× Cytokinetics Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SYY | |
|---|---|---|
Market Cap | $10.63B | $40.32B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $91.16 |
52-Week Low | $34.31 | $69.30 |
Enterprise Value | $10.74B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
SYY trades at $85.24, up 1.63% with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings of $1.53 EPS, beating estimates, with revenue growth to $81.37B in 2025. Analyst consensus is bullish with 60% buy ratings and an $88.25 price target. Recent news highlights CEO discussions on CNBC and positive earnings coverage.
Outlook remains positive with steady revenue growth and efficiency initiatives driving margins. Risks include competitive pressures and macroeconomic uncertainty. The stock offers value with a P/S of 0.48 and dividend yield support, but high P/B of 15.12 warrants caution on valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
